Humanized mice|BioMice｜Biocytogen

Please enter keyword

OK

Please enter keyword

OK

Gene Editing

By species

By technologies

By strategies

Animal & Cell Models

Humanized animal models

Immune checkpoint humanized mice

Cytokine humanized mice

GPCR humanized mice

Other humanized mice

KO mouse models

Drug target knockout mice

Other knockout mice

Tool mice

Other tool mice

Immunodeficient mice/rats

B-NDG series immunodeficient mice

Other immunodeficient mice/rats

Cell lines

Humanized cell lines

Mouse derived cell lines

Reporter cell lines

Other cell lines

Aged mice

Disease mouse models

Oncology Disease

Autoimmune Disease

Nervous System Disease

Metabolic Disease

Orthopedic Disease

Ophthalmic Disease

Cardiovascular diseases

Urinary System Disease

Surgical disease

Pharmacology Services

Therapeutic area

Metabolic diseases

Autoimmune diseases

Inflammatory diseases

Types of services

In vivo pharmacology

Ex vivo pharmacology

In vitro pharmacology

Pharmacokinetics (PK) assays

Pathological/Toxicological assays

Model/method development

Integrated solution

Molecule type

Peptide/protein

Technology

Other Services

Microbial detection

Animal Breeding

Animal Cryopreservation

Animal Rederivation

Resources & Activities

Technical support

News & events

About Us

Biocytogen animal center

Certifications

Join us

Contact us

Biocytogen

English|Chinese

English

Chinese

Resources&Activities

Technical support

Publications

Technical Q & A

Humanized mice

B-NDG mice

Others

B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes

Used in this study: B-h4-1BB mice. Part Author's Institute: ABL Bio Inc.

A novel human anti-TIGIT monoclonal antibody with excellent function in eliciting NK cell-mediated antitumor immunity

Used in this study: B-hTIGIT mice, B-hPD-1/hTIGIT mice. Part Author's Institute: Xijing Hospital, Fourth Military Medical University

IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis

Used in this study: B-hFcRn mice. Part Author's Institute: Innovent Biologics (Suzhou) Co., Ltd.

An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases

Used in this study: B-hFcRn mice. Part Author's Institute: Shanghai Jemincare Pharmaceuticals Co., Ltd.

The establishment of humanized IL-4/IL-4RA mouse model by gene editing and efficacy evaluation.

Used in this study: B-hIL4/hIL4RA mice. Part Author's Institute: Beijing University of Chemical Technology.

A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade.

Used in this study: B-hPD-L1 mice. Part Author's Institute: Shanghai Novamab Biopharmaceuticals Co., Ltd.

1 … 4 5 6 7 8

Technical support

News&events

Quality Assurance

Microbial detection

Animal health report

Genetic background detection

About us

+86-10-56967680

info@bbctg.com.cn

Copyright © 2024 BioMice. All Rights Reserved Powered by Fractal-technology